Innoviva, Inc. (NASDAQ:INVA)
| Market Cap | $1.31B-13.5% |
| Revenue (ttm) | $441.75M+13.7% |
| Net Income | $193.44M+51.9% |
| EPS | $1.99+47.4% |
| Shares Out | 71.08M |
| PE Ratio | 7.25 |
| Forward PE | 8.94 |
| Dividend | n/a |
| Ex-Dividend Date | Sep 8, 2015 |
| Volume | 1,146,551 |
| Open | $18.42 |
| Previous Close | $18.41 |
| Day's Range | $18.33 - $18.70 |
| 52-Week Range | $18.19 - $25.15 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | $31.50(+71.10%) |
| Earnings Date | Feb 24, 2027 |
About INVA
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.
Analyst consensus
1 firm rating INVA in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 24, 2027Earnings report
$INVA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in INVA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by INVA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
INVA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New INVA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to INVA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in INVA
| IJRiShares Core S&P Small-Cap ETF | $80.10M |
| AFTYPacer CSOP FTSE China A50 ETF | $55.51M |
| VTIVanguard Morningstar Total Stock Market ETF | $37.32M |
| IWMiShares Russell 2000 ETF | $36.83M |
| VBVanguard Morningstar Small-Cap ETF | $32.58M |
| DFSVU.S. Small Cap Value Portfolio ETF Class Shares | $26.42M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from INVA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Piper Sandler initiated coverage with Overweight rating and $29 price target; valuation analysis pieces suggest stock appeal despite quarterly loss.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| PJP | Invesco Pharmaceuticals ETF | 2.68% |
| SIXS | ETC 6 Meridian Small Cap Equity ETF | 2.02% |
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 1.79% |
| HSMV | First Trust Horizon Managed Volatility Small/Mid ETF | 1.02% |
| ECML | Euclidean Fundamental Value ETF | 0.97% |
| FSGS | First Trust SMID Growth Strength ETF | 0.90% |
| FSCS | First Trust SMID Capital Strength ETF | 0.88% |
| SCOW | Pacer Funds Trust - Pacer S&P SmallCap 600 Quality FCF Aristocrats ETF | 0.84% |
| PSCH | Invesco S&P SmallCap Health Care ETF | 0.72% |
| GRPZ | Invesco S&P SmallCap 600 GARP ETF | 0.65% |
| FYT | First Trust Small Cap Value AlphaDEX Fund | 0.54% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.51% |
Weight is the stock’s share of each fund’s holdings.
